CN114432403A - 一种宣肺败毒中药的制备方法 - Google Patents
一种宣肺败毒中药的制备方法 Download PDFInfo
- Publication number
- CN114432403A CN114432403A CN202110431293.9A CN202110431293A CN114432403A CN 114432403 A CN114432403 A CN 114432403A CN 202110431293 A CN202110431293 A CN 202110431293A CN 114432403 A CN114432403 A CN 114432403A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- chinese medicine
- traditional chinese
- decocting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 82
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 210000004072 lung Anatomy 0.000 title claims abstract description 19
- 230000001988 toxicity Effects 0.000 title claims abstract description 7
- 231100000419 toxicity Toxicity 0.000 title claims abstract description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 41
- 241000218671 Ephedra Species 0.000 claims abstract description 22
- 235000001759 Citrus maxima Nutrition 0.000 claims abstract description 21
- 244000276331 Citrus maxima Species 0.000 claims abstract description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 21
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 21
- 235000011477 liquorice Nutrition 0.000 claims abstract description 21
- 240000000011 Artemisia annua Species 0.000 claims abstract description 18
- 235000001405 Artemisia annua Nutrition 0.000 claims abstract description 18
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 18
- 240000002505 Pogostemon cablin Species 0.000 claims abstract description 18
- 235000011751 Pogostemon cablin Nutrition 0.000 claims abstract description 18
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 18
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 18
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 claims abstract description 18
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 claims abstract description 18
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 claims abstract description 18
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 claims abstract description 18
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 18
- 239000010440 gypsum Substances 0.000 claims abstract description 18
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 17
- 241000801118 Lepidium Species 0.000 claims abstract description 17
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 11
- 235000003893 Prunus dulcis var amara Nutrition 0.000 claims abstract description 10
- 240000001519 Verbena officinalis Species 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 61
- 239000000463 material Substances 0.000 claims description 37
- 239000000706 filtrate Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 27
- 238000001694 spray drying Methods 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- 244000018633 Prunus armeniaca Species 0.000 claims description 7
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 description 55
- 238000004519 manufacturing process Methods 0.000 description 23
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 20
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 20
- 239000001685 glycyrrhizic acid Substances 0.000 description 20
- 229960004949 glycyrrhizic acid Drugs 0.000 description 20
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 20
- 235000019410 glycyrrhizin Nutrition 0.000 description 20
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 18
- 229930019673 naringin Natural products 0.000 description 18
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 18
- 229940052490 naringin Drugs 0.000 description 18
- 241001081203 Verbena Species 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 238000002791 soaking Methods 0.000 description 12
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 10
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 10
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 10
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 238000012795 verification Methods 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 6
- JCMWSVNNSPUNER-UHFFFAOYSA-N N,O-dimethyltyramine Chemical compound CNCCC1=CC=C(OC)C=C1 JCMWSVNNSPUNER-UHFFFAOYSA-N 0.000 description 6
- 238000007908 dry granulation Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 5
- 238000012827 research and development Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011020 pilot scale process Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000013341 scale-up Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 229960002179 ephedrine Drugs 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010042727 Swollen tongue Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 230000003616 anti-epidemic effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种宣肺败毒中药的制备方法,该中药是由麻黄300份、石膏1500份、麸炒苍术500份、广藿香750份、青蒿600份、虎杖1000份、马鞭草1500份、薏苡仁1500份、芦根1500份、葶苈子750份、苦杏仁750份、化橘红750份、甘草500份,该制备方法具有生产工艺步骤简化、质量可控性良好,并获得的产品有效物质含量高,且质量稳定、疗效显著的特点。
Description
技术领域
本发明属于中药学领域,具体涉及一种宣肺败毒中药的制备方法。
背景技术
本发明所述中药为宣肺败毒颗粒,已由山东步长制药股份有限公司独家生产。收录于《新型冠状病毒肺炎诊疗方案(试行第六版、第七版)》中。宣肺败毒方的组方是由麻黄、苦杏仁、生石膏、薏苡仁、苍术、广藿香、青蒿、虎杖、马鞭草、芦根、葶苈子、化橘红、甘草组成,具有宣肺化湿、清热透邪、泻肺解毒的功效。主治湿毒郁肺证,用于治疗新型冠状病毒感染肺炎普通型,症见发热,咳嗽痰少,或有黄痰,憋闷气促,腹胀,大便不畅。舌质暗红,舌体胖,苔黄腻或黄燥,脉滑数或弦滑。该药用于湿毒郁肺所致的疫病,为新冠肺炎治疗提供了更多用药选择。
对此,本发明的申请人对该产品从中药组方、工艺参数改进、中药有效物质成分、药理药效试验等方面,进行了大量科学探索研究,并布局一系列专利申请,其中申请号分别为:202010265774.2、202011269872.X、202010832621.1、202010833756.X、202010832609.0,上述专利技术保护主题大多集中在组方配比、制备方法、质量检测方法等方面。本发明宣肺败毒方在新冠肺炎临床救治过程中,根据临床观察总结出来的有效方剂,在阻断新冠肺炎病情转重、改善症状,特别是在缩短病程方面有良好的疗效。而本专利申请是依据中医药理论、人用经验,临床救治的疗效和所取得的科学数据的基础上,还原临床实践用药摸索优化而得,并找到了工业化大生产中较佳的制备工艺参数,以期提高本发明中药的内在质量的稳定性。
发明内容
本发明的是提供一种宣肺败毒中药的制备方法,该制备方法具有生产工艺步骤简化、质量可控性良好,并获得的产品有效物质含量高,且质量稳定、疗效显著的特点。
本发明所采用的技术方案是:
一种宣肺败毒中药的制备方法,所述制备方法包括如下步骤:
取麻黄300份、石膏1500份、苍术500份、广藿香750份、青蒿600份、虎杖1000份、马鞭草1500份、薏苡仁1500份、芦根1500份、葶苈子750份、苦杏仁750份、化橘红750份、甘草500份,加水煎煮提取1-2次,并加入上述药材重量3~10倍量的水,煎煮时间为20~90分钟,合并水煎煮滤液,滤液减压浓缩,干燥成干膏粉,再加入药剂学上常用的辅料制成各种不同口服制剂,即得。
优选的,所述制备方法中加水煎煮1次,加入药材重量4~6倍量的水,煎煮时间为30~50分钟,煎煮温度90~100℃。
优选的,所述制备方法中加水煎煮2次,加入药材重量4~8倍量的水,煎煮时间为30~60分钟。
优选的,所述制备方法中减压浓缩温度为55~65℃,真空度为-0.04~-0.12MPa。
优选的,所述制备方法中的辅料为甘露醇、乳糖、淀粉、糊精、微晶纤维素、丙二醇。
优选的,所述制备方法中的辅料为甘露醇、乳糖。
优选的,所述制备方法中的辅料中甘露醇:乳糖的用量=1:2。
优选的,所述制备方法中制成的口服制剂为颗粒剂、丸剂、片剂、胶囊剂、浓缩丸剂、口服液。
优选的,所述制备方法中加水煎煮1次,加入药材重量4倍量的水,煎煮时间为40分钟。
作为本发明制备工艺的进一步优选,所述制备方法中,取麻黄300份、石膏1500份、苍术500份、广藿香750份、青蒿600份、虎杖1000份、马鞭草1500份、薏苡仁1500份、芦根1500份、葶苈子750份、苦杏仁750份、化橘红750份、甘草500份,加水煎煮提取1次,并加入上述药材重量4倍量的水,煎煮时间为40分钟,合并水煎煮滤液,滤液减压浓缩滤液减压浓缩至相对密度1.02~1.15中药浸膏,进行喷雾干燥成干膏粉,再加入药剂学上常用的辅料制成各种不同口服制剂,即得。
优选的,所述制备方法中喷雾干燥中进风温度为170±30℃,出风温度为70±30℃。
本发明所述中药所指代是宣肺败毒颗粒方,其处方配比组成为:麻黄300g、石膏1500g、麸炒苍术500g、广藿香750g、青蒿600g、虎杖1000g、马鞭草1500g、薏苡仁1500g、芦根1500g、葶苈子750g、苦杏仁750g、化橘红750g、甘草500g。
为了更加直观说明,本发明工艺技术方案的整体有益效果。我们系统梳理并整理该产品研发过程中的部分资料,以期证明本发明技术方案的创造性。
1.1本发明制备工艺提取参数工艺研究
我们依据中药制备工艺特点以及同类药物临床应用时的用法用量来作为基础,进行相应的研究,以加水至没过药材3-5cm和一个处方量药材可煎煮出400ml药液为参考指标,并系统考察一倍处方量、三倍处方量、五倍处方量和十倍处方量,分别置于1L、3L、8L和20L的煎药机中考察,加入不同加水倍量没过药材的高度以及煎煮后所得药液量,从而确定加水用溶剂量。根据药物初期临床应用的煎煮方案,取5倍处方量,依据加水可以没过药材3-5cm的加水倍量4倍水和4.5倍水量进行煎煮考察。
试验结果显示:加4倍量水浸泡30分钟,加热沸腾,并煎煮40分钟后可以获得2L(400ml*5)药液;而4.5倍水量可以获得2.6L(400ml*6.5),超出了400ml/单处方量的参考标准。
因此,最终确定了模拟抗疫一线的宣肺败毒汤的提取工艺参数为:采用五倍处方量加4倍水,浸泡30分钟,加热至沸腾,煎煮40分钟,并得到2L药液的制备工艺。
在本发明中药在研发过程中,为了更好与临床抗疫一线使用的宣肺败毒汤保持一致,我们采用处方组成和剂量和水煎煮提取4倍量与临床应用基本一致。在制备颗粒剂辅料筛选过程中,试验发现采用甘露醇与乳糖(2:1)作为复配辅料,其制剂的稳定性和成型性最好。
1.2本发明制备工艺浓缩工艺参数优化
为了最大程度保障中药提取液的有效成分不会因浓缩温度过高,或长期受热浓缩而发生改变,并且提高生产研发效率,本发明提取滤液控制浓缩温度为60±5℃下减压真空浓缩,从而保证产品的提取液在相对较低温度下快速浓缩至相对密度1.02~1.10(60℃测)的浸膏。
1.3本发明制备工艺喷雾干燥工艺参数优化
本发明中药提取浸膏,采用喷雾干燥的方式干燥。控制进风温度180±20℃,进风温度达到规定要求后,开动排风机,使排风温度升至80±20℃。开启喷雾干燥机,打开进料阀和进料泵,调整料液流量,以流通平稳、雾化状态良好,进风、排风温度稳定为准。物料进入喷雾干燥机内,开始喷雾干燥至水分≤6.0%。所得本发明中药干浸膏粉,分装密闭存放,存放时间应≤30天,干浸膏粉收率约在5.2%~7.8%。
1.4剂型选择与规格确定
剂型选择:古代经典名方中药复方制剂的研究指南中建议汤剂开发成颗粒剂,颗粒剂剂型工艺简便易行,且开水冲服,与古代经典名方的汤剂更为接近。宣肺败毒颗粒全方由《伤寒论》麻杏石甘汤、《金匮要略》麻杏薏甘汤、葶苈大枣泻肺汤、《外台秘要》苇茎汤、《太平惠民和剂局方》不换金正气散5个经典名方化裁而来,且在抗疫一线使用的是宣肺败毒汤,为了保持和临床用宣肺败毒汤的一致性,选择颗粒剂。
规格确定:基于宣肺败毒方在抗疫一线的临床使用情况和宣肺败毒颗粒中试、中试放大生产和工艺验证生产的产品的产率和指标成分的转移率。宣肺败毒方的一个人日服用临床剂量的处方量(238g)等同于生产获取的宣肺败毒颗粒2袋,每袋10g。因此得出以下结论;按照本发明制备工艺生产获取的中药相当于临床上全方量的宣肺败毒汤,确定本发明中药的规格为每袋装10g(相当于饮片119g)。
1.5本发明中药颗粒含量测定及含量限度制定
1.5.1麻黄碱含量测定
本发明中药颗粒中以君药麻黄中药效成分盐酸麻黄碱与盐酸伪麻黄碱,化橘红中柚皮苷及甘草中甘草酸为指标成分,依据三批中试放大生产的颗粒(批号:210204、210205、210206)及工艺验证批的颗粒剂(批号:210207、210208、210209)按照盐酸麻黄碱、盐酸伪麻黄碱含量测定,并按照其上述产品的转移率以及中国药典2020年版,规定的原料药材的指标成分含量,其中,本发明中药颗粒成品以一袋的规格为10g,综合分析制定其含量标准限度。
表1本发明生产工艺3批次中药中麻黄碱含量测定结果
表2本发明生产工艺验证3批次颗粒麻黄碱含量测定结果
由表1和表2结果可知,经中试放大生产测得3批颗粒剂中每袋含麻黄以盐酸麻黄碱(C10H15NO·HCl)和盐酸伪麻黄碱(C10H15NO·HCl)总量计15.8mg/袋。经三批次大生产测得3批颗粒剂中每袋含麻黄以盐酸麻黄碱(C10H15NO·HCl)和盐酸伪麻黄碱(C10H15NO·HCl)总量计14.8mg/袋。
研发过程中从小试到中试再到大生产获得的15批宣肺败毒颗粒中二者含量变化为7.7~16.4mg/袋。借鉴中试生产、中试放大生产和生产工艺验证获取的宣肺败毒颗粒剂中指标成分含量的平均转移率为依据,折算颗粒剂中含盐酸麻黄碱与盐酸伪麻黄碱的总量为12.4mg/袋,在此基础上下浮动50%,作为宣肺败毒颗粒中的盐酸麻黄碱与盐酸伪麻黄碱含量的上下限。因此宣肺败毒颗粒每袋含麻黄以盐酸麻黄碱(C10H15NO·HCl)和盐酸伪麻黄碱(C10H15NO·HCl)的总量计应为6.2~18.6mg。1.5.2本发明颗粒中柚皮苷和甘草酸含量测定
取本发明生产工艺大生产的颗粒剂(批号:210204、210205、210206)及工艺验证批的颗粒剂(批号:210207、210208、210209)按照柚皮苷、甘草酸含量测定液相色谱分析,按照其上述产品的转移率以及中国药典2020年版,规定的原料药材的指标成分含量,其中,本发明中药颗粒成品以一袋的规格为10g,综合分析制定其含量标准限度,本发明颗粒中的柚皮苷和甘草酸测定结果见表3-4。
表3本发明生产工艺3批次颗粒中柚皮苷和甘草酸含量测定结果
表4本发明工艺验证3批次颗粒中柚皮苷和甘草酸含量测定结果
表3-4试验结果显示,经中试放大生产三批宣肺败毒颗粒的测定结果为:本品每袋含柚皮苷201.2mg;含甘草酸15.1mg。经生产工艺验证三批宣肺败毒颗粒的测定结果为:本品每袋含柚皮苷28.3mg;含甘草酸14.7mg。研发过程从小试、中试到生产工艺验证获得的15批宣肺败毒颗粒中柚皮苷的含量变化为16.9~24.3mg/g。
参考中试放大生产和生产工艺验证获取颗粒剂中柚皮苷含量的平均转移率为依据,折算出颗粒剂中柚皮苷的含量为247mg/袋,在此基础上下浮50%,作为宣肺败毒颗粒中柚皮苷含量的标准上下限。即:宣肺败毒颗粒每袋含化橘红以柚皮苷计应为123.5~370.5mg。
参考中试生产及生产工艺验证获取的颗粒剂中甘草酸含量的转移率为依据,折算出颗粒剂中甘草酸的最低含量为8.1mg/袋。此外实验过程中,选用的甘草中甘草酸含量差异较大,研发过程从小试、中试到生产工艺验证获得的15批宣肺败毒颗粒中柚皮苷的含量变化为1.44~1.76mg/g。甘草酸的转移率差异较大,导致宣肺败毒颗粒的甘草酸含量差异较大,因此依据甘草酸的含量下限8.1mg/袋为基础上浮四倍即32.4mg/袋作为宣肺败毒颗粒中甘草酸含量的标准上限。即:宣肺败毒颗粒每袋含甘草以甘草酸(C42H62O16)计应为8.1~32.4mg。
本发明中药制备方法的有益效果
⑴、本发明中药的制备工艺最大的创新点在于,本专利申请工艺依据“中医理论-人用经验-临床试验”的基础上,以临床疗效价值为主导,还原该宣肺败毒方在临床用药实践中优化而得,并摸索研究中找到了工业化大生产较佳的制备工艺参数。采用上述十三味中药材,进行混合煎煮,并采用较少4倍量水进行单次提取,得水煎液,其有较高浓度的中药活性成分,并在临床治疗新冠病毒患者中取得显著的临床疗效。
本发明优化的制备工艺路线选择原则是:保证产品“安全、有效、质量可控”的目标。本发明还基于抗疫一线的临床标准煎液,以加水没过药材3-5cm,一个临床宣肺败毒处方量(238g)煎煮获取400mL药液为参考标准,研发摸索本发明生产提取工艺参数,保证生产的宣肺败毒颗粒与临床应用中的宣肺败毒汤的收率和有效物质成分的转移率基于保持一致,因此可知,按照本发明工艺生产获取的宣肺败毒颗粒相当于临床上全方量的宣肺败毒汤。
⑵、本发明制备工艺的还具有步骤简化、质量控制稳定性高的优点。按照本发明最佳制备工艺制得的成品,依据质量标准进行检测。中试放大生产的宣肺败毒颗粒(批号:210204、210205、210206)盐酸麻黄碱和盐酸伪麻黄碱总量转移率分别为13.84%,12.40%,13.75%;柚皮苷的含量转移率分别为21.51%,20.73%,16.48%;甘草酸的含量转移率分别为11.32%,10.65%,11.54%;各项质量指标均符合要求,其质量稳定。基于本发明中药中试放大生产的产品与模拟抗疫一线临床标准煎液,其两者提取的出液量一致即收率一致,转移率基本一致,指标成分含量相近。
本发明优化确定生产工艺参数,经过3批大生产及3批工艺验证,其制得的中药颗粒剂中的盐酸麻黄碱和盐酸伪麻黄碱、柚皮苷、甘草酸有效成分含量稳定可靠。从而为本发明中药的临床疗效提供有力保障。
⑶、采用本发明制备工艺制得中药,具有产品内在质量稳定可靠,从而保证其临床上的疗效。按照本发明制备工艺制得颗粒剂有效物质含量均匀稳定。通过质量检测可知,本发明中药每袋(10克)所含麻黄以含盐酸麻黄碱(C10H15NO·HCl)和盐酸伪麻黄碱(C10H15NO·HCl)总量计应为6.2~18.6mg;含化橘红以柚皮苷(C27H32O14)计应为123.5~370.5mg;含甘草以甘草酸(C42H62O16)计应为8.1~32.4mg。
具体实施方式
以下是本发明的具体实施例,对本发明的技术方案做进一步作描述,但是本发明的保护范围并不限于这些实施例。凡是不背离本发明构思的改变或等同替代均包括在本发明的保护范围之内。
本发明所述中药所指的是宣肺败毒方,其处方配比组成为:麻黄300g、石膏1500g、麸炒苍术500g、广藿香750g、青蒿600g、虎杖1000g、马鞭草1500g、薏苡仁1500g、芦根1500g、葶苈子750g、燀苦杏仁750g、化橘红750g、甘草500g。
本发明的中药经过水提取制得干膏粉,所选用药用辅料包括制备生产中药制剂中适用的任何辅料,只要该药用辅料不对本发明的中药内在质量和性能产生不利影响即可。中药中常用的辅料有蔗糖、乳糖、淀粉、糊精、微晶纤维素、硬脂酸并制成口服制剂的颗粒剂、胶囊剂、浓缩丸剂、滴丸剂等。本领域技术人员根据本说明书公开的内容能够选择和确定本发明的中药组合物中适用的辅料及其含量。
实施例1本发明颗粒剂的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取1次,并加入上述药材重量4倍量的水,浸泡30分钟,加热至沸腾,煎煮温度95~100℃,煎煮时间为40分钟,合并水煎煮滤液,滤液在减压浓缩温度为60~65℃,真空度为-0.06~-0.10MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为170±30℃,出风温度为70±30℃,喷雾制成干膏粉,加入乳糖和甘露醇适量(乳糖:甘露醇=2:1),混合均匀,干法制粒,制成颗粒剂。
实施例2本发明颗粒剂的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取1次,并加入上述药材重量6倍量的水,浸泡30分钟,煎煮温度90~100℃,每次煎煮时间为30分钟,合并水煎煮滤液,滤液在减压浓缩温度为58~63℃,真空度为-0.06~-0.10MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为180±20℃,出风温度为80±20℃,喷雾制成干膏粉,加入淀粉和微晶纤维素适量,混合均匀,干法制粒,制成颗粒剂。
实施例3本发明颗粒剂的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取1次,并加入上述药材重量3倍量的水,浸泡30分钟,煎煮温度95~99℃,煎煮时间为30分钟,合并水煎煮滤液,滤液在减压浓缩温度为60~63℃,真空度为-0.06~-0.09MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为190±10℃,出风温度为80±20℃,喷雾制成干膏粉,加入糊精和蔗糖适量,混合均匀,干法制粒,制成颗粒剂。
实施例4本发明颗粒剂的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取1次,并加入上述药材重量10倍量的水,浸泡30分钟,煎煮温度95~100℃,煎煮时间为30分钟,合并水煎煮滤液,滤液在减压浓缩温度为58~62℃,真空度为-0.05~-0.09MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为180±20℃,出风温度为80±20℃,喷雾制成干膏粉,加入乳糖和微晶纤维素适量,混合均匀,干法制粒,制成颗粒剂。
实施例5本发明片剂的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取2次,并加入上述药材重量6倍量的水,浸泡20分钟,煎煮温度96~100℃,煎煮时间为50分钟,合并水煎煮滤液,滤液在减压浓缩温度为57~62℃,真空度为-0.06~-0.10MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为180±10℃,出风温度为80±10℃,喷雾制成干膏粉,再加入乳糖、预胶化淀粉,混合均匀后。采用75%乙醇适量,进行制粒干燥,压制成片剂。
实施例6本发明胶囊剂的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取2次,并加入上述药材重量4倍量的水,浸泡50分钟,加热至沸腾,煎煮温度96~100℃,煎煮时间为40分钟,合并水煎煮滤液,滤液在减压浓缩温度为58~64℃,真空度为-0.05~-0.12MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为180±10℃,出风温度为80±20℃,喷雾制成干膏粉,加入羧甲基淀粉钠、乳糖、糊精适量,混合均匀,再加入85%乙醇湿法制粒,制粒,干燥,可得,本发明胶囊剂。
实施例7本发明滴丸剂的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取2次,并加入上述药材重量8倍量的水,浸泡40分钟,加热至沸腾,煎煮温度98~100℃,煎煮时间为40分钟,合并水煎煮滤液,滤液在减压浓缩温度为55~65℃,真空度为-0.06~-0.10MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为180±20℃,出风温度为80±10℃,喷雾制成干膏粉,再加入PEG4000、PEG6000、硬脂酸适量,混合均匀,滴制成滴丸剂。
实施例8本发明浓缩丸的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取1次,并加入上述药材重量5倍量的水,浸泡30分钟,加热至沸腾,煎煮温度96~99℃,煎煮时间为40分钟,合并水煎煮滤液,滤液在减压浓缩温度为55~65℃,真空度为-0.06~-0.10MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为170±30℃,出风温度为70±30℃,喷雾制成干膏粉,加入适量蜂蜜,混合均匀,制成将丸剂,并于62℃减压干燥4h,制成浓缩丸。
实施例9本发明颗粒剂的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取1次,并加入上述药材重量9倍量的水,浸泡30分钟,加热至沸腾,煎煮温度90~99℃,煎煮时间为90分钟,合并水煎煮滤液,滤液在减压浓缩温度为62~65℃,真空度为-0.05~-0.09MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为180±10℃,出风温度为80±20℃,喷雾制成干膏粉,加入甘露醇和蔗糖适量,混合均匀,干法制粒,制成颗粒剂。
实施例10本发明颗粒剂的制备
⑴、取麻黄、虎杖、苦杏仁、马鞭草、生石膏、芦根、薏苡仁、葶苈子、苍术、化橘红、广藿香、甘草、青蒿,加水煎煮提取2次,并加入上述药材重量5倍量的水,浸泡30分钟,加热至沸腾,煎煮温度90~99℃,煎煮时间为20分钟,合并水煎煮滤液,滤液在减压浓缩温度为62~65℃,真空度为-0.05~-0.09MPa下,浓缩至相对密度1.02~1.10中药浸膏(60℃);
⑵、取步骤⑴中药浸膏,进行喷雾干燥,其中进风温度为180±10℃,出风温度为80±20℃,喷雾制成干膏粉,加入甘露醇和蔗糖适量,混合均匀,干法制粒,制成颗粒剂。
Claims (10)
1.一种宣肺败毒中药的制备方法,其特征在于,所述制备方法包括如下步骤:
取麻黄300份、石膏1500份、苍术500份、广藿香750份、青蒿600份、虎杖1000份、马鞭草1500份、薏苡仁1500份、芦根1500份、葶苈子750份、苦杏仁750份、化橘红750份、甘草500份,加水煎煮提取1-2次,并加入上述药材重量3~10倍量的水,煎煮时间为20~90分钟,合并水煎煮滤液,滤液减压浓缩,干燥成干膏粉,再加入药剂学上常用的辅料制成各种不同口服制剂,即得。
2.如权利要求1所述中药的制备方法,其特征在于,所述制备方法中加水煎煮1次,加入药材重量4~6倍量的水,煎煮时间为30~50分钟,煎煮温度90~100℃。
3.如权利要求1所述中药的制备方法,其特征在于,所述制备方法中加水煎煮2次,加入药材重量4~8倍量的水,煎煮时间为30~60分钟。
4.如权利要求1所述中药的制备方法,其特征在于,所述制备方法中减压浓缩温度为55~65℃,真空度为-0.04~-0.12MPa。
5.如权利要求1所述中药的制备方法,其特征在于,所述制备方法中的辅料为甘露醇、乳糖、淀粉、糊精、微晶纤维素、丙二醇。
6.如权利要求5所述中药的制备方法,其特征在于,所述制备方法中的辅料为甘露醇、乳糖。
7.如权利要求6所述中药的制备方法,其特征在于,所述制备方法中的辅料中甘露醇:乳糖的用量=1:2。
8.如权利要求1所述中药的制备方法,其特征在于,所述制备方法中加水煎煮1次,加入药材重量4倍量的水,煎煮时间为40分钟。
9.如权利要求1所述中药的制备方法,其特征在于:所述制备方法中,取麻黄300份、石膏1500份、苍术500份、广藿香750份、青蒿600份、虎杖1000份、马鞭草1500份、薏苡仁1500份、芦根1500份、葶苈子750份、苦杏仁750份、化橘红750份、甘草500份,加水煎煮提取1次,并加入上述药材重量4倍量的水,煎煮时间为40分钟,合并水煎煮滤液,滤液减压浓缩滤液减压浓缩至相对密度1.02~1.15中药浸膏,进行喷雾干燥成干膏粉,再加入药剂学上常用的辅料制成各种不同口服制剂,即得。
10.如权利要求9所述中药的制备方法,其特征在于:所述制备方法中喷雾干燥中进风温度为170±30℃,出风温度为70±30℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110431293.9A CN114432403A (zh) | 2021-04-21 | 2021-04-21 | 一种宣肺败毒中药的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110431293.9A CN114432403A (zh) | 2021-04-21 | 2021-04-21 | 一种宣肺败毒中药的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114432403A true CN114432403A (zh) | 2022-05-06 |
Family
ID=81362420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110431293.9A Pending CN114432403A (zh) | 2021-04-21 | 2021-04-21 | 一种宣肺败毒中药的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114432403A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111789918A (zh) * | 2020-04-07 | 2020-10-20 | 天津中医药大学 | 一种抗冠状病毒的中药组合物及其制备方法和用途 |
-
2021
- 2021-04-21 CN CN202110431293.9A patent/CN114432403A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111789918A (zh) * | 2020-04-07 | 2020-10-20 | 天津中医药大学 | 一种抗冠状病毒的中药组合物及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
王春燕;王希营;金红;: "新型冠状病毒肺炎诊疗方案(试行第七版)", 兰州大学学报(医学版), no. 02, pages 7 - 13 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022036779A1 (zh) | 化湿败毒颗粒及其制备方法和抗病毒药物 | |
CN107050304A (zh) | 一种无糖型二岩虎果中药颗粒剂的制备方法 | |
WO2021120972A1 (zh) | 一种治疗气血两虚症候的中药组合物及其制备方法和应用 | |
CN107495367A (zh) | 一种提高耐缺氧能力的食品、保健品或药物组合物及其制备方法和用途 | |
CN102526477A (zh) | 一种增强免疫力的药物组合物及其制备方法和应用 | |
CN101700289B (zh) | 治疗胃肠功能紊乱或肠易激综合症的中药提取物组合物、制备方法及其在制备药物中的应用 | |
CN102614281B (zh) | 一种提高缺氧耐受力的中药组合物及其制备方法和应用 | |
CN111729054A (zh) | 化湿败毒中药组合物、中药制剂及其制备方法和应用 | |
CN102319357B (zh) | 一种降脂灵分散片及其制备工艺 | |
CN103550164B (zh) | 一种益气健脾的归脾丸(微丸) | |
CN108721564B (zh) | 一种治疗血小板减少症的药物组合物及其制备方法和用途 | |
CN102961584B (zh) | 一种抗疲劳的中药组合物及其制备方法和应用 | |
CN100376287C (zh) | 半夏泻心汤制剂及其制备方法和应用 | |
CN112516219B (zh) | 一种治疗系统性红斑狼疮中药颗粒的制备工艺 | |
CN114432403A (zh) | 一种宣肺败毒中药的制备方法 | |
CN115531463A (zh) | 一种治疗高脂血症的中药 | |
CN104547588B (zh) | 一种胃康灵滴丸的制备方法 | |
CN110420275B (zh) | 一种八正胶囊及其制备方法 | |
CN104257839B (zh) | 一种具有降糖降脂保护血管内皮作用的中药组合物及其制备方法 | |
CN105998244B (zh) | 一种用于慢性心衰的中药制剂 | |
CN113827570A (zh) | 一种基于药物载体技术制备中药微丸制剂的方法及其应用 | |
CN106109625B (zh) | 一种用于心衰治疗的中药制剂的制备方法 | |
CN106421727A (zh) | 一种用于治疗痛经的中药组合物及其制备方法与应用 | |
CN107997170B (zh) | 一种具有降血脂功能的组合物及其制备方法 | |
CN103494894A (zh) | 一种具有降低血糖功效的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220506 |
|
RJ01 | Rejection of invention patent application after publication |